ClinicalTrials.gg
CompletedNCT04906421Updated May 9, 2025Results posted

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of TVB-2640 and Placebo in Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease, sponsored by Sagimet Biosciences Inc.. Completed at 117 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-09.

Sponsored by Sagimet Biosciences Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
97th of 460
168 · median 56
Started
2021
with 56 others
Phase 2
192 of 547
15 open now
Registered
402nd of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 97th largest by enrollment of the 460 interventional ones that give a count, is one of 57 that started in 2021, is one of 192 in phase 2, and was the 402nd registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy on TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH). Subjects will be randomly assigned toTVB-2640 or matching placebo PO QD for 52 weeks, with the first dose administered on Day 1.

Read the detailed description

The indication nonalcoholic steatohepatitis [NASH]) is now referred to as metabolic dysfunction-associated steatohepatitis (MASH) and is characterized by hepatocyte necrosis, chronic inflammation, and resultant fibrosis formation.

03

Conditions studied

  • Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease

Keywords

  • NASH
  • Nonalcoholic Steatohepatitis
  • Fatty Liver Disease
  • Biopsy Confirmed
  • FASN
  • Fatty Liver
  • Liver Disease
  • Digestive System Diseases
  • MASH
  • Metabolic dysfunction-associated steatohepatitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be willing and able to participate in the study and provide written .
  • Male and female adults ≥18 years of age on the date that written informed consent to take part in the study is provided.
  • (BMI) ≥23 kg/m2 for Asians and ≥25 kg/m2 for other races.
  • Female subjects must be either:

    • Not of OR
    • Women of childbearing potential (WOCBP) must have a negative serum pregnancy (beta-human chorionic gonadotropin [β-HCG]) test during Screening, a negative urine pregnancy test within 24 hours before the first dose of study drug on Day 1, and must agree to perform urine home pregnancy tests monthly between study visits. WOCBP must not be breastfeeding, not plan to become pregnant during the study, and must use .
  • Must have liver stiffness measurement ≥8.5 kPa measured by FibroScan and CAP score measured by FibroScan ≥280 dB/m during the Screening period.
  • Histologic confirmation of NASH: must have had prior liver within 180 days before randomization (randomization is within 24 hours of Baseline [Day1]) with fibrosis stage F2-F3 and a NAS of ≥4 with at least a score of 1 in each of the following NAS components: steatosis, ballooning degeneration, and lobular inflammation.

Exclusion criteria

Exclusion Criteria:

  • History of harmful alcohol intake for a period of more than 3 consecutive months within 1 year prior to Screening in the judgement of the Investigator.
  • Active substance abuse.
  • Gain or loss of >5% of body weight in the 6 months prior to Baseline (Day 1) or >10% of body weight in the 12 months prior to Screening.
  • Type 1 diabetes mellitus by history.
  • Positive severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) polymerase chain reaction (PCR) test within 30 days before Baseline, history of hospitalization for coronavirus disease-2019 (COVID-19) ), or history of use of oxygen due to COVID-19) \<6 months prior to the Screening visit date. Note that previous COVID-19 infection alone is not exclusionary and vaccination against SARS-CoV-2 is allowed. Infection and/or vaccination must be documented.
  • Uncontrolled T2DM, defined as ≥9.5% at Screening.
  • Presence of cirrhosis on liver histology (stage 4 fibrosis), according to the judgement of the central reader, and/or cross sectional imaging evidence consistent with cirrhosis and/or portal hypertension.
  • Use of glucagon-like peptide-1 (GLP-1) agonists or a sodium-glucose co-transporter-2 (SGLT2) inhibitor, unless on a stable daily dose for at least 6 months prior to the Screening visit date, or on a complex oral anti-diabetic (OAD) regimen (3 or more OADs [except for a GLP-1 agonist or an SGLT2 inhibitor]), unless on a stable dose for at least 3 months prior to the Screening visit date.
  • Subjects with active or quiescent chronic liver disease of etiologies other than NASH (eg, viral or hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, and 'autoimmune hepatitis-overlap' syndromes, hemochromatosis, Wilson's disease, alpha 1 antitrypsin deficiency, alcohol-related liver disease, drug-induced liver disease, and/or infiltrative conditions [eg, sarcoidosis]).
  • Current or historic clinically evident hepatic decompensation event (eg, ascites formation, variceal hemorrhage, hepatic encephalopathy).
  • Any subject who has sustained a clinically evident cardiovascular, cerebrovascular, and/or peripheral vascular event during the 12 months prior to anticipated Baseline (Day 1) visit date is not eligible for study participation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    TVB-2640 50 mg

    Subjects will receive TVB-2640 PO QD for 52 weeks, with the first dose administered on Day 1.

    Drug: TVB-2640

  • Placebo comparator
    Placebo

    Subjects will receive matching placebo PO QD for 52 weeks, with the first dose administered on Day 1.

    Other: Placebo

Interventions

  • Oral dose, tablet

  • OtherPlacebo

    Oral dose, tablet

06

What researchers measure

Primary outcomes

  1. Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis Score).

    Histological improvement is defined as ≥2 points improvement in NAS with ≥1 point improvement in ballooning or inflammation

    Time frame: 52 Weeks

  2. Subjects With Resolution of Steatohepatitis and No Worsening of Liver Fibrosis by NASH CRN Fibrosis Score and Histological Improvement in NAS.

    NASH resolution defined as absence of fatty liver disease or isolated or simple steatosis without steatohepatitis and a score of either 0 or 1 for inflammation, 0 for ballooning and any value for steatosis and no worsening of liver fibrosis (by NASH CRN fibrosis score). Histological improvement defined as ≥2 point improvement in NAS (with ≥1 point improvement in ballooning or inflammation).

    Time frame: 52 Weeks

Secondary outcomes

  1. Proportion of Subjects Experiencing Fibrosis Improvement of ≥1 Stage by NASH CRN Score Without Worsening of Steatohepatitis

    Proportion of subjects experiencing fibrosis improvement of ≥1 stage by NASH CRN score Without worsening of steatohepatitis (defined as no increase in NAS for ballooning, inflammation, or steatosis) at 52 weeks.

    Time frame: 52 Weeks

  2. Proportion of Subjects Experiencing Resolution of Steatohepatitis and no Worsening of Liver Fibrosis (by NASH CRN Fibrosis Score)

    Resolution of steatohepatitis is defined as absence of fatty liver disease or isolated or simple steatosis without steatohepatitis and a NAS of 0 or 1 for inflammation, 0 for ballooning, and any value for steatosis.

    Time frame: 52 Weeks

  3. Proportion of Subjects With Improvement in Liver Fibrosis >=1 Stage by NASH CRN Fibrosis Score Without Worsening of Steatohepatitis at 52 Weeks OR Resolution of Steatohepatitis and No Worsening of Liver Fibrosis by NASH CRN Fibrosis Score

    No increase in NAS for ballooning, inflammation or steatosis.

    Time frame: 52 Weeks

  4. Proportion of MRI-PDFF ≥30% Responders.

    MRI PDFF ≥30% responder is defined as a subject with ≥8% liver fat content at Baseline who achieves a relative reduction from Baseline in MRI-PDFF ≥30%.

    Time frame: 52 Weeks

07

Results

Posted May 9, 2025

Participant flow

Participant flow — Overall Study
MilestoneTVB-2640 50 mgPlacebo
Started11256
Mitt8145
Completed8047
Not completed329

Outcome measures

PrimaryHistological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis Score).

Histological improvement is defined as ≥2 points improvement in NAS with ≥1 point improvement in ballooning or inflammation

Time frame:
52 Weeks
Reported as:
Count of participants · Participants
Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis Score).
ParticipantsITT: TVB-2640 50 mgITT: PlacebomITT: TVB-2640 50 mgmITT: Placebo
Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis Score).429429
Statistical analysis
  • ITT: TVB-2640 50 mg vs ITT: Placebo · Cochran-Mantel-Haenszel · p = 0.0018 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)One-sided
  • ITT: TVB-2640 50 mg vs ITT: Placebo · Cochran-Mantel-Haenszel · p = 0.0035 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)Two-sided
  • mITT: TVB-2640 50 mg vs mITT: Placebo · t-test, 1 sided · p = 0.0001 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)One-sided
  • mITT: TVB-2640 50 mg vs mITT: Placebo · Cochran-Mantel-Haenszel · p = 0.0003 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)Two-sided
PrimarySubjects With Resolution of Steatohepatitis and No Worsening of Liver Fibrosis by NASH CRN Fibrosis Score and Histological Improvement in NAS.

NASH resolution defined as absence of fatty liver disease or isolated or simple steatosis without steatohepatitis and a score of either 0 or 1 for inflammation, 0 for ballooning and any value for steatosis and no worsening of liver fibrosis (by NASH CRN fibrosis score). Histological improvement defined as ≥2 point improvement in NAS (with ≥1 point improvement in ballooning or inflammation).

Time frame:
52 Weeks
Reported as:
Count of participants · Participants
Subjects With Resolution of Steatohepatitis and No Worsening of Liver Fibrosis by NASH CRN Fibrosis Score and Histological Improvement in NAS.
ParticipantsITT: TVB-2640 50 mgITT: PlacebomITT: TVB-2640 50 mgmITT: Placebo
Subjects With Resolution of Steatohepatitis and No Worsening of Liver Fibrosis by NASH CRN Fibrosis Score and Histological Improvement in NAS.296296
Statistical analysis
  • ITT: TVB-2640 50 mg vs ITT: Placebo · Cochran-Mantel-Haenszel · p = 0.0087 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)One-sided
  • ITT: TVB-2640 50 mg vs ITT: Placebo · Cochran-Mantel-Haenszel · p = 0.0173 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)Two-sided
  • mITT: TVB-2640 50 mg vs mITT: Placebo · Cochran-Mantel-Haenszel · p = 0.0022 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)One-sided
  • mITT: TVB-2640 50 mg vs mITT: Placebo · Cochran-Mantel-Haenszel · p = 0.0044 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)Two-sided
SecondaryProportion of Subjects Experiencing Fibrosis Improvement of ≥1 Stage by NASH CRN Score Without Worsening of Steatohepatitis

Proportion of subjects experiencing fibrosis improvement of ≥1 stage by NASH CRN score Without worsening of steatohepatitis (defined as no increase in NAS for ballooning, inflammation, or steatosis) at 52 weeks.

Time frame:
52 Weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Experiencing Fibrosis Improvement of ≥1 Stage by NASH CRN Score Without Worsening of Steatohepatitis
ParticipantsmITT: TVB-2640 50 mgmITT: PlaceboSubgroup: Fibrosis Stage F2; TVB-2640Subgroup: Fibrosis Stage F2; PlaceboSubgroup: Fibrosis Stage F3; TVB-2640Subgroup: Fibrosis Stage F3; PlaceboSubgroup: T2DM; TVB-2640Subgroup: T2DM; Placebo
Proportion of Subjects Experiencing Fibrosis Improvement of ≥1 Stage by NASH CRN Score Without Worsening of Steatohepatitis338105233225
Statistical analysis
  • mITT: TVB-2640 50 mg vs mITT: Placebo · Cochran-Mantel-Haenszel · p = 0.0102 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)Two-sided
  • Subgroup: Fibrosis Stage F2; TVB-2640 vs Subgroup: Fibrosis Stage F2; Placebo · Cochran-Mantel-Haenszel · p = 0.59 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)Two-sided
  • Subgroup: Fibrosis Stage F3; TVB-2640 vs Subgroup: Fibrosis Stage F3; Placebo · Cochran-Mantel-Haenszel · p = 0.0032 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)Two-Sided
  • Subgroup: T2DM; TVB-2640 vs Subgroup: T2DM; Placebo · Cochran-Mantel-Haenszel · p = 0.0764 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)Two-sided
SecondaryProportion of Subjects Experiencing Resolution of Steatohepatitis and no Worsening of Liver Fibrosis (by NASH CRN Fibrosis Score)

Resolution of steatohepatitis is defined as absence of fatty liver disease or isolated or simple steatosis without steatohepatitis and a NAS of 0 or 1 for inflammation, 0 for ballooning, and any value for steatosis.

Time frame:
52 Weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Experiencing Resolution of Steatohepatitis and no Worsening of Liver Fibrosis (by NASH CRN Fibrosis Score)
ParticipantsmITT: TVB-2640 50 mgmITT: Placebo
Proportion of Subjects Experiencing Resolution of Steatohepatitis and no Worsening of Liver Fibrosis (by NASH CRN Fibrosis Score)317
Statistical analysis
  • mITT: TVB-2640 50 mg vs mITT: Placebo · Cochran-Mantel-Haenszel · p = 0.0043 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)Two-sided
SecondaryProportion of Subjects With Improvement in Liver Fibrosis >=1 Stage by NASH CRN Fibrosis Score Without Worsening of Steatohepatitis at 52 Weeks OR Resolution of Steatohepatitis and No Worsening of Liver Fibrosis by NASH CRN Fibrosis Score

No increase in NAS for ballooning, inflammation or steatosis.

Time frame:
52 Weeks
Reported as:
Count of participants · Participants
Proportion of Subjects With Improvement in Liver Fibrosis >=1 Stage by NASH CRN Fibrosis Score Without Worsening of Steatohepatitis at 52 Weeks OR Resolution of Steatohepatitis and No Worsening of Liver Fibrosis by NASH CRN Fibrosis Score
ParticipantsmITT: TVB-2640 50 mgmITT: Placebo
Proportion of Subjects With Improvement in Liver Fibrosis >=1 Stage by NASH CRN Fibrosis Score Without Worsening of Steatohepatitis at 52 Weeks OR Resolution of Steatohepatitis and No Worsening of Liver Fibrosis by NASH CRN Fibrosis Score4512
Statistical analysis
  • mITT: TVB-2640 50 mg vs mITT: Placebo · Cochran-Mantel-Haenszel · p = 0.0018 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)Two-sided
SecondaryProportion of MRI-PDFF ≥30% Responders.

MRI PDFF ≥30% responder is defined as a subject with ≥8% liver fat content at Baseline who achieves a relative reduction from Baseline in MRI-PDFF ≥30%.

Time frame:
52 Weeks
Reported as:
Count of participants · Participants
Proportion of MRI-PDFF ≥30% Responders.
ParticipantsmITT: TVB-2640 50 mgmITT: Placebo
Proportion of MRI-PDFF ≥30% Responders.6938
Statistical analysis
  • mITT: TVB-2640 50 mg vs mITT: Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Stratified CMH test stratified by T2DM status at baseline (yes or no) and amount of fibrosis at baseline (F2 or F3).)Two-sided

Adverse events

Collected over 12 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TVB-2640 50 mg0/112 (0%)13/112 (11.6%)79/112 (70.5%)
Placebo0/56 (0%)3/56 (5.4%)36/56 (64.3%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventTVB-2640 50 mgPlacebo
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1121/56
Subcapsular hepatic haematomaHepatobiliary disorders0/1121/56
BronchoscopyInvestigations0/1121/56
PneumothoraxRespiratory, thoracic and mediastinal disorders0/1121/56
CellulitisInfections and infestations1/1120/56
EmpyemaInfections and infestations1/1120/56
Norovirus infectionInfections and infestations1/1120/56
Ophthalmic herpes zosterInfections and infestations1/1120/56
Pneumonia parainfluenzae viralInfections and infestations1/1120/56
UrosepsisInfections and infestations1/1120/56
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTVB-2640 50 mgPlacebo
AlopeciaSkin and subcutaneous tissue disorders21/1122/56
COVID-19Infections and infestations19/1126/56
Dry EyeEye disorders10/1128/56
Urinary tract infectionInfections and infestations9/1123/56
Dry skinSkin and subcutaneous tissue disorders7/1120/56
DiarrhoeaGastrointestinal disorders7/1123/56
SinusitisInfections and infestations6/1122/56
ConstipationGastrointestinal disorders5/1123/56
NauseaGastrointestinal disorders5/1123/56
HeadacheNervous system disorders5/1123/56

Baseline characteristics

Age, Continuous
Age, Continuous(years)TVB-2640 50 mgPlaceboTotal
Mean56.3 ± 10.558.4 ± 11.957.0 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)TVB-2640 50 mgPlaceboTotal
Female6634100
Male462268
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TVB-2640 50 mgPlaceboTotal
Hispanic or Latino342155
Not Hispanic or Latino7835113
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TVB-2640 50 mgPlaceboTotal
American Indian or Alaska Native000
Asian314
Native Hawaiian or Other Pacific Islander101
Black or African American7411
White10050150
More than one race000
Unknown or Not Reported112
08

Study locations

117 sites
  • North Alabama Health Research
    Huntsville, Alabama 35801, United States
  • North Alabama GI Research Center
    Madison, Alabama 35758, United States
  • GI Alliance Arizona Digestive Health-Sun City
    Sun City, Arizona 85351, United States
  • ARcare Center for Clinical Research, LLC - Conway
    Conway, Arkansas 72032, United States
  • Arkansas Diagnostic Center
    Little Rock, Arkansas 72205, United States
  • Liver Wellness Center
    Little Rock, Arkansas 72205, United States
  • Citrus Valley Gastroenterology
    Covina, California 91723, United States
  • UCSD, NAFLD Research Center / Altman Clinical and Translational Research Institute
    La Jolla, California 92093, United States
  • Om Research LLC
    Lancaster, California 93534, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Digestive Health Research of Southern California LLC
    Long Beach, California 90808, United States
  • Digestive Health Research of Southern California
    Long Beach, California 90808, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • United Medical Doctors
    Murrieta, California 92563, United States
  • Palmtree Clinical Research, INC
    Palm Springs, California 92262, United States
  • IVGI
    Ventura, California 93003, United States
  • Gastro Florida
    Clearwater, Florida 33761, United States
  • Tampa Bay Medical Research, Inc.
    Clearwater, Florida 33761, United States
  • American Research Institute, Inc
    Cutler Bay, Florida 33157, United States
  • Top Medical Research, Inc
    Cutler Bay, Florida 33189, United States
  • Covenant Metabolic Specialists, LLC
    Fort Myers, Florida 33912, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
  • Miguel A Rebollar, MD PA
    Hialeah, Florida 33012, United States
  • Global Research Associates
    Homestead, Florida 33030, United States
  • Ocala GI Research dba Lake Center for Clinical Research, LLC
    Lady Lake, Florida 32159, United States
  • Accel Research Site - Maitland
    Maitland, Florida 32751, United States
  • Panax Clinical Research
    Miami Lakes, Florida 33014, United States
  • San Marcus Research Clinic, Inc.
    Miami Lakes, Florida 33014, United States
  • CPMI
    Miami, Florida 33014, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Sanchez Clinical Research, Inc
    Miami, Florida 33157, United States
  • Genoma Research Group, Inc
    Miami, Florida 33173, United States
  • Professional Medical Research
    Miramar, Florida 33025, United States
  • Ocala GI Research, LLC
    Ocala, Florida 34471, United States
  • Innovation Medical Research Center, Inc
    Palmetto Bay, Florida 33157, United States
  • Pensacola GI Research Center, LLC
    Pensacola, Florida 32503, United States
  • Covenant Metabolic Specialists, LLC
    Sarasota, Florida 34240, United States
  • Headlands Research Sarasota
    Sarasota, Florida 34243, United States
  • Conquest Research
    Winter Park, Florida 32789, United States
  • Summit Clinical Research
    Athens, Georgia 30607, United States
  • Southeast Clinical Research Center
    Dalton, Georgia 30720, United States
  • Care Access Research
    Fairview Heights, Illinois 62208, United States
  • Gastroenterology Health Partners, PLLC
    New Albany, Indiana 47150, United States
  • Digestive Research Alliance of Michiana
    South Bend, Indiana 46635, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Kansas Medical Clinic, PA
    Topeka, Kansas 66606, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • Louisiana Research Center LLC
    Shreveport, Louisiana 71105, United States
  • Woodholme Gastroenterology Associates
    Glen Burnie, Maryland 21061, United States
  • Greater Boston Gastroenterology
    Boston, Massachusetts 01702, United States
  • Greater Boston Gastroenterology
    Framingham, Massachusetts 01702, United States
  • FC Research LLC
    South Dartmouth, Massachusetts 02747, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • GI Associates Research, LLC
    Columbia, Missouri 65201, United States
  • Sierra Clinical Research
    Las Vegas, Nevada 89106, United States
  • Jubilee Clinical Research, Inc.
    Las Vegas, Nevada 899106, United States
  • Care Access
    Yonkers, New York 10701, United States
  • University of North Carolina at Chapel Hill. UNC Liver Center
    Chapel Hill, North Carolina 27599, United States
  • Northeast GI Research Division
    Concord, North Carolina 28027, United States
  • ACME Medical Specialties PLCC
    Lumberton, North Carolina 28358, United States
  • Care Access Research
    Lumberton, North Carolina 28358, United States
  • Lucas Research, Inc.
    Morehead City, North Carolina 28557, United States
  • Trial Management Associates, LLC
    Wilmington, North Carolina 28403, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • DSI Research, LLC - Northridge
    Dayton, Ohio 45414, United States
  • Care Access Research
    Poland, Ohio 44514, United States
  • DDSI Clinical Trials
    Oklahoma City, Oklahoma 73112, United States
  • University of Gastroenterology
    Providence, Rhode Island 02905, United States
  • Care Access Research
    Warwick, Rhode Island 02886, United States
  • Ralph H. Johnson Veterans Affairs Medical Center
    Charleston, South Carolina 29401, United States
  • Columbia Digestive Health Research, LLC
    Columbia, South Carolina 29204, United States
  • Digestive Disease Research Center LLC
    Greenwood, South Carolina 29646, United States
  • Rapid City Medical Center, LLP
    Rapid City, South Dakota 57701, United States
  • WR-ClinSearch, LLC
    Chattanooga, Tennessee 37421, United States
  • Gastro One
    Cordova, Tennessee 38018, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Digestive Health Research
    Lebanon, Tennessee 37090, United States
  • Texas Clinical Research Institute, LLC
    Arlington, Texas 76012, United States
  • Pinnacle Clinical Research
    Austin, Texas 78557, United States
  • Apex Mobile Clinical Research, LLC
    Bellaire, Texas 77401, United States
  • Texas Digestive Disease Consultants - Cedar Park
    Cedar Park, Texas 78613, United States
  • The Liver Institute at Methodist Health System
    Dallas, Texas 75203, United States
  • GI Alliance -Texas Digestive Disease Consultants
    Dallas, Texas 75246, United States
  • South Texas Research Institute
    Edinburg, Texas 78539, United States
  • Texas Digestive Disease Consultants - Fort Worth
    Fort Worth, Texas 76104, United States
  • Baylor College of Medicine - Advanced Liver Therapies
    Houston, Texas 77030, United States
  • Pioneer Research Solutions
    Houston, Texas 77099, United States
  • GI Alliance / Texas Digestive Disease Consultants
    Lubbock, Texas 79410, United States
  • Centex Studies
    McAllen, Texas 78504, United States
  • ClinRx Research LLC
    Plano, Texas 75023, United States
  • American Research Corporation
    San Antonio, Texas 78215, United States
  • Clinical Trials of Texas Inc.
    San Antonio, Texas 78229, United States
  • Diabetes and Glandular Disease Clinic, P.A.
    San Antonio, Texas 78229, United States
  • Endeavor Clinical Trials, LLC
    San Antonio, Texas 78229, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 78240, United States
  • Sherman Clinical Research
    Sherman, Texas 75092, United States
  • Impact Research Institute
    Waco, Texas 76710, United States
  • Digestive Health Research of North Texas
    Wichita Falls, Texas 76301, United States
  • Care Access
    Ogden, Utah 84403, United States
  • Bon Secours Richmond Community Hospital LLC d/b/a Bon Secours Liver Institute of Richmond
    Richmond, Virginia 23226, United States

Showing the first 100 of 117 sites across 4 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Loomba R, Bedossa P, Grimmer K, Kemble G, Bruno Martins E, McCulloch W, O'Farrell M, Tsai WW, Cobiella J, Lawitz E, Rudraraju M, Harrison SA. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2024 Dec;9(12):1090-1100. doi: 10.1016/S2468-1253(24)00246-2. Epub 2024 Oct 11. PubMed 39396529 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Oct 2023, 25 months.

Results were first posted in May 2025, 1 year 7 months after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 25 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2021
First posted
May 28, 2021
StartActual
Aug 12, 2021
Primary completionActual
Oct 2, 2023
CompletionActual
Oct 2, 2023
Results first posted
May 9, 2025
Last update
May 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04906421
Lead sponsor
Sagimet Biosciences Inc.
Responsible party
Sponsor
First posted
May 28, 2021
Start date
Aug 12, 2021
Primary completion
Oct 2, 2023
Completion
Oct 2, 2023
Results posted
May 9, 2025
Last update
May 9, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TVB-2640

Start the discussion